Sam Brusco, Associate Editor01.12.22
Upper extremity orthopedics firm Catalyst OrthoScience has named Carl O’Connell as its new president and CEO, effective immediately. He replaces Brian Hutchison, who is stepping down.
Hutchison joined Catalyst as executive chairman and interim CEO in 2018 becfore being asked to stay on as CEO later that year. He will remain a significant company investor and serve as an advisor.
“We are pleased to have Carl step in as president and CEO of Catalyst OrthoScience,” Carter McNabb, managing director at RC Capital (fka River Cities Capital) and a member of the Catalyst board of directors told the press. “We thank Brian for the work he has done to build this company to where it is today.”
“I am excited to join the Catalyst team and continue the company’s trajectory of significant, sustainable growth,” said O’Connell. “I will be focused on ensuring a smooth transition for our employees, our distributors and our customers over the coming months. I look forward to the commercial launch and expansion of the Archer™ R1 Reverse Shoulder System, as well as continuing to enhance our product portfolio to maintain Catalyst’s leadership position in the marketplace.”
O’Connell held leadership positions at Xtant Medical, Wright Medical, Stryker, and most recently at Cerebrotech Medical systems, a company that develops portable, non-invasive neurotechnology to improve outcomes for stroke patients receiving neurological assessment.
Hutchison joined Catalyst as executive chairman and interim CEO in 2018 becfore being asked to stay on as CEO later that year. He will remain a significant company investor and serve as an advisor.
“We are pleased to have Carl step in as president and CEO of Catalyst OrthoScience,” Carter McNabb, managing director at RC Capital (fka River Cities Capital) and a member of the Catalyst board of directors told the press. “We thank Brian for the work he has done to build this company to where it is today.”
“I am excited to join the Catalyst team and continue the company’s trajectory of significant, sustainable growth,” said O’Connell. “I will be focused on ensuring a smooth transition for our employees, our distributors and our customers over the coming months. I look forward to the commercial launch and expansion of the Archer™ R1 Reverse Shoulder System, as well as continuing to enhance our product portfolio to maintain Catalyst’s leadership position in the marketplace.”
O’Connell held leadership positions at Xtant Medical, Wright Medical, Stryker, and most recently at Cerebrotech Medical systems, a company that develops portable, non-invasive neurotechnology to improve outcomes for stroke patients receiving neurological assessment.